Timothy Graul, PhD

Pfizer, Inc
Director in the Global CMC Advisory Office
Timothy W. Graul is a Director in the global CMC advisory office at Pfizer, Inc. At Pfizer, Tim supported the development of drug product formulations and drug substance synthetic routes by providing analytical methods, data, and strategy as a member of analytical R&D. Tim has been recognized as a leader in Quality by Design for analytical methods and has collaborated on publications in this area. He was recently appointed as the PhRMA Deputy Topic lead on the ICH Q2/Q14 Expert Working Group. Tim has been a member of industry groups including Land O’ Lakes Pharmaceutical Analysis Conference Planning Committee, IQ groups such as Analytical Leadership, AQbD, Dissolution, Control Strategy Harmonization Metrics, and Worldwide Specification Harmonization. He holds a PhD in Analytical Chemistry from Florida State University.

Related Articles

Figure 3: Industry develops a single global control strategy.
Features
Toward a Single Global Control Strategy: Industry Study

During the past decade, industry has experienced a proliferation of regulatory divergence regarding the interpretation and implementation of International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) guidelines (and control strategies) across geographic regions. This article shares data that highlight instances where well-established ICH...

Article
Technical
Defining the Analytical Target Profile

Analytical target profile criteria for judging the quality of results generated by analytical methods are framed in an optimization paradigm by illustrating the ATP criteria as a loss function. In the case where specifications are based on quality arguments and process capability, a probability-defined loss function is useful for providing a direct measurement of risk for making incorrect...